A randomized control study of the efficacy of asymmetrical high flow nasal cannula interface in patients with acute exacerbation of interstitial pneumonia.

A randomized control study of the efficacy of asymmetrical high flow nasal cannula interface in patients with acute exacerbation of interstitial pneumonia. - A randomized control study of the efficacy of asymmetrical high flow nasal cannula interface in patients with acute exacerbation of interstitial pneumonia.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056316

Enrollment

Registered

2024-12-19

Start date

2024-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial pneumonia

Interventions

Participants wear symmetrical high flow nasal cannula interface at least six hours, then switch to asymmetrical high flow nasal cannula interface. Participants wear asymmetrical high flow nasal cannu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients hospitalized Kurashiki central hospital because of acute exacerbation of interstitial pneumonia and received high-flow nasal therapy, who underwent methylprednisolone pulse therapy within 10 days and began rehabilitation.

Exclusion criteria

Exclusion criteria: Difference of 10% or more in required FiO2 of high flow therapy at rest between the day of the registration and the day before the registration. Intolerance to high flow therapy. Cognitive disorder. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The minimum SpO2 during rehabilitation	—

Countries

Japan

Contacts

Public ContactAkihiko Amano

Kurashiki Central Hospital Department of Respiratory Medicine

aa16513@kchnet.or.jp0864220210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026